MicroPort Endovascular MedTech Ltd (688016) - Net Assets
Based on the latest financial reports, MicroPort Endovascular MedTech Ltd (688016) has net assets worth CN¥4.24 Billion CNY (≈ $620.35 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.79 Billion ≈ $701.48 Million USD) and total liabilities (CN¥554.42 Million ≈ $81.13 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of MicroPort Endovascular MedTech Ltd to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥4.24 Billion |
| % of Total Assets | 88.43% |
| Annual Growth Rate | 60.31% |
| 5-Year Change | 466.55% |
| 10-Year Change | N/A |
| Growth Volatility | 117.8 |
MicroPort Endovascular MedTech Ltd - Net Assets Trend (2016–2025)
This chart illustrates how MicroPort Endovascular MedTech Ltd's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of MicroPort Endovascular MedTech Ltd to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for MicroPort Endovascular MedTech Ltd (2016–2025)
The table below shows the annual net assets of MicroPort Endovascular MedTech Ltd from 2016 to 2025. For live valuation and market cap data, see 688016 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥8.62 Billion ≈ $1.26 Billion |
+125.60% |
| 2024-12-31 | CN¥3.82 Billion ≈ $559.35 Million |
-1.06% |
| 2023-12-31 | CN¥3.86 Billion ≈ $565.36 Million |
+121.71% |
| 2022-12-31 | CN¥1.74 Billion ≈ $255.00 Million |
+14.49% |
| 2021-12-31 | CN¥1.52 Billion ≈ $222.73 Million |
+23.35% |
| 2020-12-31 | CN¥1.23 Billion ≈ $180.57 Million |
+15.76% |
| 2019-12-31 | CN¥1.07 Billion ≈ $155.98 Million |
+393.15% |
| 2018-12-31 | CN¥216.16 Million ≈ $31.63 Million |
+14.97% |
| 2017-12-31 | CN¥188.02 Million ≈ $27.51 Million |
+52.39% |
| 2016-12-31 | CN¥123.38 Million ≈ $18.05 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to MicroPort Endovascular MedTech Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 29108.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.45 Billion | 36.38% |
| Other Comprehensive Income | CN¥3.96 Billion | 99.36% |
| Total Equity | CN¥3.98 Billion | 100.00% |
MicroPort Endovascular MedTech Ltd Competitors by Market Cap
The table below lists competitors of MicroPort Endovascular MedTech Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FLEX LNG Ltd
NYSE:FLNG
|
$1.61 Billion |
|
Allied Gold Corporation
NYSE:AAUC
|
$1.61 Billion |
|
Shanghai Shyndec Pharmaceutical Co Ltd
SHG:600420
|
$1.61 Billion |
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
$1.61 Billion |
|
Digital China Information Service Co Ltd
SHE:000555
|
$1.61 Billion |
|
Compania Nationala de Transport al Energiei Electrice Transelectrica SA
RO:TEL
|
$1.61 Billion |
|
Sparebank 1 Nord-Norge
OL:NONG
|
$1.61 Billion |
|
Fulltech Fiber Glass
TWO:1815
|
$1.61 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MicroPort Endovascular MedTech Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,791,843,035 to 3,982,290,000, a change of 190,446,965 (5.0%).
- Net income of 563,213,124 contributed positively to equity growth.
- Dividend payments of 201,834,960 reduced retained earnings.
- Other comprehensive income increased equity by 3,970,516,025.
- Other factors decreased equity by 4,141,447,224.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥563.21 Million | +14.14% |
| Dividends Paid | CN¥201.83 Million | -5.07% |
| Other Comprehensive Income | CN¥3.97 Billion | +99.7% |
| Other Changes | CN¥-4.14 Billion | -104.0% |
| Total Change | CN¥- | 5.02% |
Book Value vs Market Value Analysis
This analysis compares MicroPort Endovascular MedTech Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.71x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 58.13x to 2.71x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥1.53 | CN¥89.18 | x |
| 2017-12-31 | CN¥2.34 | CN¥89.18 | x |
| 2018-12-31 | CN¥2.69 | CN¥89.18 | x |
| 2019-12-31 | CN¥11.66 | CN¥89.18 | x |
| 2020-12-31 | CN¥11.50 | CN¥89.18 | x |
| 2021-12-31 | CN¥13.94 | CN¥89.18 | x |
| 2022-12-31 | CN¥16.03 | CN¥89.18 | x |
| 2023-12-31 | CN¥35.68 | CN¥89.18 | x |
| 2024-12-31 | CN¥30.74 | CN¥89.18 | x |
| 2025-12-31 | CN¥32.88 | CN¥89.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MicroPort Endovascular MedTech Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.14%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 41.70%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.17x
- Recent ROE (14.14%) is below the historical average (22.18%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 33.32% | 32.81% | 0.66x | 1.53x | CN¥28.78 Million |
| 2017 | 33.71% | 38.38% | 0.74x | 1.19x | CN¥44.58 Million |
| 2018 | 41.94% | 39.22% | 0.86x | 1.24x | CN¥69.03 Million |
| 2019 | 13.30% | 42.48% | 0.29x | 1.08x | CN¥35.16 Million |
| 2020 | 17.39% | 45.64% | 0.34x | 1.12x | CN¥91.22 Million |
| 2021 | 21.14% | 46.14% | 0.39x | 1.17x | CN¥166.43 Million |
| 2022 | 20.76% | 39.81% | 0.45x | 1.16x | CN¥185.01 Million |
| 2023 | 12.81% | 41.48% | 0.28x | 1.10x | CN¥108.05 Million |
| 2024 | 13.24% | 41.62% | 0.28x | 1.13x | CN¥122.92 Million |
| 2025 | 14.14% | 41.70% | 0.29x | 1.17x | CN¥164.98 Million |
Industry Comparison
This section compares MicroPort Endovascular MedTech Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $3,442,122,104
- Average return on equity (ROE) among peers: 12.05%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MicroPort Endovascular MedTech Ltd (688016) | CN¥4.24 Billion | 33.32% | 0.13x | $1.61 Billion |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $4.98 Billion | -4.70% | 0.37x | $371.06 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $2.13 Billion | 17.09% | 0.37x | $3.63 Billion |
| Double Medical Technology Inc (002901) | $3.11 Billion | 2.98% | 0.27x | $2.56 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $6.77 Billion | 62.15% | 0.36x | $506.97 Million |
| Lepu Medical Tech Beijing (300003) | $10.54 Billion | 17.10% | 0.73x | $3.19 Billion |
| INKON Life Technology Co Ltd (300143) | $343.97 Million | 0.00% | 1.34x | $764.39 Million |
| Edan Instruments Inc (300206) | $1.25 Billion | 3.50% | 0.14x | $1.15 Billion |
| Guangdong Biolight Meditech Co Ltd (300246) | $1.39 Billion | -4.69% | 0.82x | $735.30 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $761.02 Million | 12.92% | 0.49x | $467.29 Million |
| Sinocare Inc (300298) | $3.14 Billion | 14.20% | 0.47x | $1.17 Billion |
About MicroPort Endovascular MedTech Ltd
Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft syste… Read more